Clinical Trials Browser

Interventional × Cholangiocarcinoma × Folfox protocol × Clear all

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06529718 2026-05-19

SEVILLA

Phase 2 Recruiting

72 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06840886 2026-05-14

A Study of PHST001 in Advanced Solid Tumors

Phase 1 Recruiting

272 enrolled

CNSGastrointestinalGynecologic

Ovarian Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07265674 2026-05-14

Beacon-BTC

Phase 3 Recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Phase 2 Not yet recruiting

36 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06946849 2025-04-27

SED-RO-ICC

Phase 2 Not yet recruiting

76 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05124002 2024-03-04

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Phase 4 Unknown

66 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05535647 2022-09-10

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Unknown

60 enrolled

Gastrointestinal

Cholangiocarcinoma

Clinical Trials

BOLSTER

SEVILLA

A Study of PHST001 in Advanced Solid Tumors

Beacon-BTC

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

SED-RO-ICC

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma